Antifibrotic drugs (nidanib or pirfenidone)

ApprovedSmall molecule

SShanghai Pulmonary Hospital, Shanghai, China

Antifibrotic drugs (nidanib or pirfenidone) is one of 89 small molecule programs targeting Interstitial Lung Disease. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Interstitial Lung DiseaseActive, not recruiting

SclerodermaActive, not recruiting

Interstitial Lung DiseaseApproved

Active, not recruiting

SclerodermaPreclinical

Active, not recruiting

Competition

Competitive Landscape

85 competitors in Interstitial Lung Disease

#DrugCompanyPhaseTrials

Cellcept

Roche

Phase 3

4 2

Rituxan

Roche

Phase 3

4 3

Cialis

Eli Lilly

Phase 3

1 4

Actemra

Roche

Phase 3

1 5

Prograf

VVeloxis Pharmaceuticals

Phase 3

1 6

Jascayd

Boehringer Ingelheim

Phase 3

1 7

Benlysta

GGlaxo Dba Glaxosmithkline

Phase 3

1 8

Orencia

Bristol-Myers Squibb

Phase 2

2 9

Elavil

AstraZeneca

Phase 2

1 10

Remodulin

United Therapeutics

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Recruiting

Scleroderma

NCT07491523

Q2 2028

Post-ApprovalNot yet recruiting

Interstitial Lung Disease

NCT07141810

Clinical

Trials by Indication[1]

Scleroderma1 trial

Double Immunosuppression With or Without Anti-fibrotic in Scleroderma ILD

Recruiting·UUniversity of Patras··NCT07491523·35 enrolled

Interstitial Lung Disease1 trial

Efficacy and Safety of Early Antifibrotic Therapy for Non-progressive Fibrotic Interstitial Lung Disease

Not yet recruiting·SShanghai Pulmonary Hospital, Shanghai, China·Phase 4·NCT07141810·104 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Antifibrotic drugs (nidanib or pirfenidone). U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Antifibrotic drugs (nidanib or pirfenidone) compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Antifibrotic drugs (nidanib or pirfenidone). EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Shanghai Pulmonary Hospital, Shanghai, China company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: SShanghai Pulmonary Hospital, Shanghai, China

Antifibrotic drugs (nidanib or pirfenidone)

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q2 2028

Trials by Indication[1]

Scleroderma1 trial

Interstitial Lung Disease1 trial

References

Drug Info

Quick Facts

Related News